← Back to Clinical Trials
Recruiting NCT04490720

NCT04490720 The Efficacy Evaluation of Buckwheat Husk Extract on Cardiovascular Disease Risk Factors

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT04490720
Status Recruiting
Phase
Sponsor TCI Co., Ltd.
Condition Cardiovascular Diseases
Study Type INTERVENTIONAL
Enrollment 60 participants
Start Date 2021-11-24
Primary Completion 2025-12-31

Eligibility & Interventions

Sex All sexes
Min Age 20 Years
Max Age 65 Years
Study Type INTERVENTIONAL
Interventions
PlaceboBuckwheat husk extract

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 60 participants in total. It began in 2021-11-24 with a primary completion date of 2025-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

To assess the efficacy evaluation of buckwheat husk extract on cardiovascular disease risk factors

Eligibility Criteria

Inclusion Criteria: 1. 20 to 65-year-old males or non-pregnant females who are willing to sign the subject's consent. 2. The systolic blood pressure is 121-139 mmHg and the diastolic blood pressure is between 81-89 mmHg. 3. Those who are not pregnant and are willing to cooperate with contraception during the trial period. 4. No history of organ transplantation, epilepsy or convulsions, liver or kidney disease, malignant tumor, endocrine disease, mental disease, alcohol or drug abuse, or other major organic diseases (according to medical history). Exclusion Criteria: 1. Pregnant women. 2. People with a history of organ transplantation, epilepsy or convulsions, liver and kidney disease, malignant tumors, endocrine diseases, mental illness, alcohol or drug abuse, and other major organic diseases (according to medical history). 3. No person has undergone major surgery.

Contact & Investigator

Central Contact

Shyr-Chyr Chen

✉ scchen@ntu.edu.tw

📞 (02) 23123456

Principal Investigator

Mao-Hsin Lin, Doctor

PRINCIPAL INVESTIGATOR

National Taiwan University Hospital

Frequently Asked Questions

Who can join the NCT04490720 clinical trial?

This trial is open to participants of all sexes, aged 20 Years or older, up to 65 Years, studying Cardiovascular Diseases. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT04490720 currently recruiting?

Yes, NCT04490720 is actively recruiting participants. Contact the research team at scchen@ntu.edu.tw for enrollment information.

Where is the NCT04490720 trial being conducted?

This trial is being conducted at Taipei, Taiwan.

Who is sponsoring the NCT04490720 clinical trial?

NCT04490720 is sponsored by TCI Co., Ltd.. The principal investigator is Mao-Hsin Lin, Doctor at National Taiwan University Hospital. The trial plans to enroll 60 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology